Tyrosine kinase inhibitor for kidney cancer

Votrient (pazopanib) is indicated for the treatment of advanced renal cell carcinoma (RCC), both as first-line treatment and following previous cytokine therapy.

Pazopanib is a potent inhibitor of multiple tyrosine kinases: vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, platelet-derived growth factor receptors (PDGFR)-α and –β, and stem cell factor receptor (c-KIT). By inhibiting angiogenesis, pazopanib deprives kidney tumour cells of their oxygen supply.

In a randomised, double-blind, multicentre study in 435 patients with locally advanced and/or metastatic RCC, median progression-free survival was 9.2 months with pazopanib 800mg daily compared with 4.2 months on placebo, equating to a 54 per cent relative reduction in the risk of disease progression with pazopanib (p<0.0001).

View Votrient drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in